NCT05822609View on ClinicalTrials.gov

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Diabetic Kidney DiseaseType 1 Diabetes
Interventions
DRUG

Semaglutide

1.0 mg

OTHER

Placebo

Placebo

Trial Locations (4)

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

98104

RECRUITING

University of Washington, Seattle

99204

RECRUITING

Providence Sacred Heart Medical Center, Spokane

M5G2N2

RECRUITING

Toronto General Hospital, University Health Network, Toronto

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

Providence Healthcare

OTHER

collaborator

University of Toronto

OTHER

lead

University of Washington

OTHER